AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02383173 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Basic Implementation Approach
Description: Comfort Care Education Intervention utilizing the established infrastructure of Palliative Care Consult Teams, using a Basic Implementation Approach with a teleconference to review educational materials and activate PCCTs to educate other providers.
Study NCT02383173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Implementation Approach
Description: Comfort Care Education Intervention utilizing the established infrastructure of Palliative Care Consult Teams, using an Enhanced Implementation Approach with in-person, train-the-champion workshops to prepare PCCT members to be leaders and trainers at their home sites
Study NCT01804907 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Study NCT01804907 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Behavioral Modification
Study NCT01667614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: spironolacone 25 mg tablets added to losartan
Description: spironolactone 25 mg once daily added to losartan
Study NCT03215615 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal surgery
Description: Coronally advanced flap for root coverage
Study NCT03215615 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Etch adhesive
Description: Total-etch adhesive system (two step)
Study NCT03215615 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Universal Adhesive
Description: One-step self-etching adhesive system
Study NCT03215615 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nanofilled Composite
Description: Partial nanofilled-resin composite restoration
Study NCT03215615 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Micro-Hybrid Composite
Description: Partial micro-hybrid composite restoration
Study NCT02412319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-HBV placenta transfer factor injection
Description: Anti-HBV Placenta Transfer Factor Injection: 2mg/4ml, intramuscular injection, the 0-24 week, once every other day; week 24-48, 2 times / week; entecavir tablets: 0.5mg/ tablet / time, daily bedtime fasting oral once, treatment course 96 weeks
Study NCT02412319 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Physiological saline injection: 2mg/4ml, intramuscular injection,the 0-24 week, once every other day, week 24-48, 2 times / week; entecavir tablets: 0.5mg/ tablet / time, daily bedtime fasting oral once, treatment course 96 weeks
Study NCT02575625 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fibroscan
Description: Three series oh independent measures Measure done with Fibroscan will be preceded by tracking ultrasonography.
Study NCT02575625 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood test for biological assessment of liver function
Description: Blood test for biological assessment of liver function
Study NCT02575625 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Liver MRI
Study NCT01713738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: infusion of 4 weekly doses of 375 mg/m2 rituximab
Study NCT01297244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib
Description: Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
Study NCT01531153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Galantamine
Description: 8mg or 16mg
Study NCT01531153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo dose.
Study NCT01324180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Will be dosed orally BID as per dose level of subject as defined in dose escalation schema. Both liquid and tablet forms are allowed and can be chosen based on convenience. Metformin will be continued throughout the cycle until Day 28 or until the patient is removed from study (e.g. to pursue new lines of therapy such as transplant), whichever occurs sooner.
Study NCT01324180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.5 mg/m\^2/dose IV push (maximum single dose 2 mg) on days 2, 9, 16 and 23
Study NCT01324180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: * 10 mg/m\^2/day divided BID~* Take dexamethasone by mouth days 2-15
Study NCT01324180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-asparaginase
Description: * 2500 IU's/m\^2/day~* Intramuscular injection (IM) or intravenous infusion per institutional standard on days 3, 9, 16 and 23~* If the patient develops an allergic reaction to PEG while being treated on this protocol, eliminate all future doses of PEG and substitute Erwinia if not intolerant of Erwinia and has no history of pancreatitis.~* Patients will receive Erwinase® 25,000 IU/m\^2 x 6 doses intramuscularly (IM) on a Monday/Wednesday/Friday schedule as a replacement for each scheduled dose of PEG-asparaginase on the original protocol.
Study NCT01324180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 60 mg/m\^2/day IV over 15 minutes on day 2
Study NCT01324180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal chemotherapy
Description: IT cytarabine given intrathecally to all patients on day 1 of each cycle. Dose defined by age. May be given with staging lumbar puncture before enrollment, but must be within 72 hours of starting therapy. If not done at study entry or before, may be done on Day 2 prior to doxorubicin administration.~* 30 mg for patients age 1-1.99~* 50 mg for patients age 2-2.99~* 70 mg for patients greater than 3 years of age IT methotrexate given Intrathecally to all patients who are CNS negative at study entry on day 16 at the dose defined by age.
Study NCT02744768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Adult Ph+ ALL (≥18 years old, with no upper age limit) patients will begin treatment with Dasatinib, 140 mg/day, from day 1 to day +84.
Study NCT02744768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Upon induction:~patients in CHR will receive Blinatumomab at a dose of 15 µg/m²/day as continuous intravenous infusion (CIVI) at a constant flow rate for four weeks, followed by a two-week infusion-free interval, defined as one treatment cycle. At least 2 cycles should be administered, up to a maximum of 5 cycles, if deemed necessary.
Study NCT01576393 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based Family Therapy
Description: 12 home-based family therapy sessions
Study NCT01576393 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: office-based family therapy
Description: 12 office-based family therapy sessions
Study NCT01576393 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: WHE
Description: 12 Women's Health Education Sessions
Study NCT02890888 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hyperbaric oxygen treatment
Description: Patients are treated in a hyperbaric oxygen chamber for 1 hour at 2ATA, 10 times over 2 consecutive weeks, 5 times per week
Study NCT00038246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estramustine
Description: 140 mg by mouth (po) three times a day on Days 1-5, 8-12
Study NCT00038246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 200 mg by mouth every day once a week with dose escalation every week if no dose limiting toxicity.
Study NCT00038246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel (Taxol)
Description: 100 mg/m\^2 by vein (IV) over 3 hours Day 3 and Day 10
Study NCT05202431 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment adherence
Description: The patients were reminded to take drug by patient training, telephone follow-up, and daily sms. It was determined that the effect of the training and telephone follow-up provided to the TB patients and contacts on the treatment adherence.
Study NCT03792997 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: combination therapy for high peripheral NK cells
Description: lipid emulsion \& prednisolone \& LMWH
Study NCT03792997 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: combination therapy for high peripheral NK cells
Description: lipid emulsion \& prednisolone \& LMWH
Study NCT04094805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocaltrol
Description: Rocaltrol 0.25 μg daily for 1 month; HD-DXM (orally at 40 mg daily for 4d )
Study NCT04094805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: HD-DXM (orally at 40 mg daily for 4d )
Study NCT01124539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-67 (7-t-butyldimethylsiltyl-10-hydroxy-camptothecin)
Description: IV AR-67 administered once daily for 5 days on an every 21-day cycle
Study NCT02874131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: Behavioral activation
Study NCT02874131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Description: Cognitive processing therapy
Study NCT02874131 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy
Description: Cognitive processing therapy
Study NCT05192876 — intervention group
Intervention type: RADIATION
Intervention: Radiotherapy
Description: Outcomes and adverse events using radiation therapy
Study NCT01133106 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief pleasurable events/behavioral therapy
Description: Each participant in any arm will be given an American Stroke Association article about stroke and depression, a Stroke Smart Article about caregiver depression, and a pamphlet by the Beck Institute titled Coping with Depression.~Each participant in Arms 1 and 2 will be given their own manual for the intervention sessions. The intervention consists of one in-person orientation session and 6 weekly sessions with the following topics introducing behavioral therapy, the role of pleasant events, problem-solving skills and generalization techniques. All participants' primary care provider or stroke care provider will receive a letter informing them of their patient's participation (but not of study assignment). This letter will include recommendations for prescribing and adjusting antidepressant treatment using established guidelines adapted for treatment of medically-ill outpatients.
Study NCT01133106 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: The standard care group (Arm C, N=75) will receive standard medical treatment from their provider, including a recommendation for antidepressants. Participants or third-party payers will pay for their antidepressants, just as they would under regular care. All participants receive written materials regarding depression from the American Stroke Association, keep medication logs and receive follow-up assessment on the same time frame as the intervention groups
Study NCT01155609 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01155609 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: management of therapy complications
Description: Discontinue supplement; treat symptomatically
Study NCT01155609 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-lysine
Description: Given PO
Study NCT04463030 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal vitamin C, 1 gram
Description: after a blood draw 1 gram of vitamin c will be consumed followed by 3 additional blood draws
Study NCT02810327 — intervention group
Intervention type: GENETIC
Intervention: Genetic Sequencing
Description: Sequencing of the SERPINA1 gene
Study NCT03251599 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Glyceryl trinitrate 0.2
Description: These patients will receive glyceryl trinitrate infusion at a rate of 0.2 mcg/kg/min throughout the rewarming period of cardiopulmonary bypass, which usually lasts for 30-45 minutes.
Study NCT04463030 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal vitamin C, 2 grams
Description: after a blood draw 2 grams of vitamin c will be consumed followed by 3 additional blood draws
Study NCT03251599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyceryl trinitrate 0.5
Description: These patients will receive glyceryl trinitrate infusion at a rate of 0.5 mcg/kg/min throughout the rewarming period of cardiopulmonary bypass, which usually lasts for 30-45 minutes.
Study NCT00756834 — intervention group
Intervention type: DEVICE
Intervention: Screening
Description: The MammoDetector™ Pro is a computer-aided software intended to identify and mark regions of interest on standard mammographic views to bring them to the attention of the radiologist after the initial reading has been completed. Thus, the device assists the radiologist in minimizing observational oversights by identifying areas on the original mammogram that may warrant a second review
Study NCT03395990 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator: chloroprocaine
Description: 15 ml of 2% chloroprocaine was placed under ultrasound guidance adjacent to the femoral nerve in the operative limb.
Study NCT03395990 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham comparator: saline
Description: 15 ml of normal saline was placed under ultrasound guidance adjacent to the femoral nerve in the operative limb.
Study NCT04687397 — intervention group
Intervention type: BEHAVIORAL
Intervention: Rehabilitation
Description: Multidisciplinary rehabilitation
Study NCT01967277 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Handi-Dome Laser
Description: One, 30 minute treatment, every other day for 16 weeks.
Study NCT01967277 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Incandescent red light source.
Description: One, 30 minute treatment, every other day for 16 weeks.
Study NCT02949453 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Semi-directed interview performed by a social sciences researcher
Description: Two semi-directed interviews performed by social sciences researcher:~* first interview performed 6 weeks after the suicide attempt, in an suicide prevention unit, duration 1 to 1.5 hour~* second interview performed 3 month after the suicide attempt, in a suicide prevention unit, duration 1 to 1.5 hour
Study NCT01967875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine+Cisplatin
Description: Cisplatin 75mg/m2, d1; Capecitabine 1700-2000mg/m2/day on days1-14 every 21 days, 6 cycles.Capecitabine is to be continued until disease progression or intolerable toxicity.
Study NCT01967875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel+Capecitabine
Description: Docetaxel 75mg/m2, d1; Capecitabine 1700-2000mg/m2/day on days1-14 every 21 days, 6 cycles. Capecitabine is to be continued until disease progression or intolerable toxicity.
Study NCT01281306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: LCZ696 was supplied as tablets in blister cards in 100 mg strengths.
Study NCT01281306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Valsartan was supplied as tablets in blister cards in 160 mg and 320 mg strengths.
Study NCT01281306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AHU377
Description: AHU377 was supplied in tablets in blister cards in 50 mg and 100 mg strengths.
Study NCT03958630 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET) Scan
Description: Participants underwent PET scan with \[11C\]ER176 and/or 11C-PIB
Study NCT04250961 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: postoperative early shower
Description: The shower group showered in 48-72 hours after median sternotomy with tap water.
Study NCT04463030 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal vitamin C, 5 grams
Description: after a blood draw 5 grams of vitamin c will be consumed followed by 3 additional blood draws
Study NCT04463030 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: after a blood draw placebo will be consumed followed by 3 additional blood draws
Study NCT01057121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide is administered daily on days 1-21 of a 28-day cycle. The maximum duration of treatment is 12 28-day cycles. Sequential cohorts were entered at 10 mg/day, 15 mg/day, 20 mg/day and 25 mg/day using a 3+3 design to determine the MTD
Study NCT00761540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Liraglutide for s.c. injection once daily: dose step 1 (9 subjects)
Study NCT00761540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Liraglutide placebo for s.c. injection once daily: dose step 1 (3 subjects)
Study NCT00761540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Liraglutide for s.c. injection once daily: dose step 1, followed by dose step 2 (9 subjects)
Study NCT00761540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Liraglutide placebo for s.c. injection once daily: dose step 1, followed by dose step 2 (3 subjects)
Study NCT00761540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Liraglutide for s.c. injection once daily: dose step 1, followed by dose steps 2 and 3 (9 subjects)
Study NCT00761540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Liraglutide placebo for s.c. injection once daily: dose step 1, followed by dose steps 2 and 3 (3 subjects)
Study NCT03880396 — intervention group
Intervention type: RADIATION
Intervention: hypofractionated Rth with platinol
Description: hypofractionated Rth with weekly cisplatin 40mg/m2
Study NCT01715025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2Nomac
Description: Women will start the first cycle of the COC on the first day of their period in the treatment phase of the study
Study NCT04345549 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualised Ayurveda
Description: Saline warm water gargle, Steam, Paracetamol for body temperature and plenty fluid and rest, Food and herbs recommendation as per individual Ayurveda constitution, Using Ginger/ lemon/ turmeric/ honey recommended as per individual, Yoga breathing
Study NCT05776537 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Fibreoptic bronchoscopy
Description: different endoscopies used for confirmation of diagnosis
Study NCT04250961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: postoperative early shower
Description: The shower group showered in 48-72 hours after median sternotomy with tap water.
Study NCT00734513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partner-assisted emotional disclosure
Description: Patients and partners in the partner-assisted emotional disclosure condition will attend four weekly face-to-face sessions with a therapist. The first session will last 75 minutes and will focus on training in skills to facilitate the patient's disclosure. The subsequent 3 sessions will last 45 minutes each. In these sessions, the therapist will briefly review the strategies and provide feedback from the previous session and the patient will spend 30 minutes talking about their cancer-related concerns to the partner.
Study NCT00734513 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cancer Education
Description: The cancer education protocol consists of four weekly face-to-face sessions for education about living with GI cancer. The cancer education sessions will be delivered to patients and their partners and use a presentation and discussion format. Handouts and discussion sessions will center on the following topics: Orientation to Duke Cancer Care and the treatment team; suggestions for communicating with health care providers; resources for health information, psychosocial support, and financial concerns; evaluating health information on the internet; the impact of cancer on different domains of quality of life; and suggestions for maintaining quality of life.
Study NCT03576027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy
Description: Hyperbaric Oxygen Therapy
Study NCT03442803 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Target-Controlled Infusion
Description: Propofol Target-Controlled Infusion
Study NCT00068731 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lycopene
Study NCT04512079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Prophylactic enoxaparin (40 mg SC QD; 30 mg SC QD for CrCl \<30 mL/min) Full-dose enoxaparin (1 mg/kg SC Q12h; 1 mg/kg SC QD for CrCl \<30 mL/min)
Study NCT04512079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: (5 mg Q12h; 2.5 mg Q12h for patients with at least two of three of age ≥80 years, weight ≤60 kg or serum creatinine ≥1.5 mg/dL)